"Global Dengue Vaccine Market Overview:
Global Dengue Vaccine Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Dengue Vaccine Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Dengue Vaccine involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Dengue Vaccine Market:
The Dengue Vaccine Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Dengue Vaccine Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Dengue Vaccine Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Dengue Vaccine market has been segmented into:
Live Attenuated Vaccines
Recombinant Vaccines
By Application, Dengue Vaccine market has been segmented into:
Phase I
Phase II
Phase III
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Dengue Vaccine market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Dengue Vaccine market.
Top Key Players Covered in Dengue Vaccine market are:
Sanofi Pasteur Limited
Takeda Pharmaceutical Company
Butantan Institute
Medigen Vaccine Biologics Corporation
GlaxoSmithKline Plc
Panacea Biotec Limited
Merck and Co. Inc.
Sun Pharma
GeneOne Life Science Inc.
Nunn’s Home Medical Equipment Company Ltd.
Serum Institute of India Pvt. Ltd.
Mylan N.V.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Dengue Vaccine Market by Type
4.1 Dengue Vaccine Market Snapshot and Growth Engine
4.2 Dengue Vaccine Market Overview
4.3 Live Attenuated Vaccines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Live Attenuated Vaccines: Geographic Segmentation Analysis
4.4 Recombinant Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Recombinant Vaccines: Geographic Segmentation Analysis
Chapter 5: Dengue Vaccine Market by Application
5.1 Dengue Vaccine Market Snapshot and Growth Engine
5.2 Dengue Vaccine Market Overview
5.3 Phase I
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Phase I: Geographic Segmentation Analysis
5.4 Phase II
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Phase II: Geographic Segmentation Analysis
5.5 Phase III
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Phase III: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Dengue Vaccine Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 SANOFI PASTEUR LIMITED
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 TAKEDA PHARMACEUTICAL COMPANY
6.4 BUTANTAN INSTITUTE
6.5 MEDIGEN VACCINE BIOLOGICS CORPORATION
6.6 GLAXOSMITHKLINE PLC
6.7 PANACEA BIOTEC LIMITED
6.8 MERCK AND CO. INC.
6.9 SUN PHARMA
6.10 GENEONE LIFE SCIENCE INC.
6.11 NUNN’S HOME MEDICAL EQUIPMENT COMPANY LTD.
6.12 SERUM INSTITUTE OF INDIA PVT. LTD.
6.13 MYLAN N.V.
Chapter 7: Global Dengue Vaccine Market By Region
7.1 Overview
7.2. North America Dengue Vaccine Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Live Attenuated Vaccines
7.2.4.2 Recombinant Vaccines
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Phase I
7.2.5.2 Phase II
7.2.5.3 Phase III
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Dengue Vaccine Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Live Attenuated Vaccines
7.3.4.2 Recombinant Vaccines
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Phase I
7.3.5.2 Phase II
7.3.5.3 Phase III
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Dengue Vaccine Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Live Attenuated Vaccines
7.4.4.2 Recombinant Vaccines
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Phase I
7.4.5.2 Phase II
7.4.5.3 Phase III
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Dengue Vaccine Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Live Attenuated Vaccines
7.5.4.2 Recombinant Vaccines
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Phase I
7.5.5.2 Phase II
7.5.5.3 Phase III
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Dengue Vaccine Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Live Attenuated Vaccines
7.6.4.2 Recombinant Vaccines
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Phase I
7.6.5.2 Phase II
7.6.5.3 Phase III
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Dengue Vaccine Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Live Attenuated Vaccines
7.7.4.2 Recombinant Vaccines
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Phase I
7.7.5.2 Phase II
7.7.5.3 Phase III
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Dengue Vaccine Scope:
|
Report Data
|
Dengue Vaccine Market
|
|
Dengue Vaccine Market Size in 2025
|
USD XX million
|
|
Dengue Vaccine CAGR 2025 - 2032
|
XX%
|
|
Dengue Vaccine Base Year
|
2024
|
|
Dengue Vaccine Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Sanofi Pasteur Limited, Takeda Pharmaceutical Company, Butantan Institute, Medigen Vaccine Biologics Corporation, GlaxoSmithKline Plc, Panacea Biotec Limited, Merck and Co. Inc., Sun Pharma, GeneOne Life Science Inc., Nunn’s Home Medical Equipment Company Ltd., Serum Institute of India Pvt. Ltd., Mylan N.V..
|
|
Key Segments
|
By Type
Live Attenuated Vaccines
Recombinant Vaccines
By Applications
Phase I
Phase II
Phase III
|
